{"schema_version":"1","generated_at":"2026-11-06T14:07:30.815Z","data_as_of":null,"url":"https://www.findmykol.com/kol/marcus-geer","json_url":"https://www.findmykol.com/kol/marcus-geer/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"marcus-geer","name":"Marcus Geer","credential":"MD","specialty":"Hematology","specialty_raw":"Hematology","therapeutic_area":"Hematology","therapeutic_areas":["Hematology"],"institution":"University of Michigan","institution_url":"https://www.findmykol.com/institution/university-of-michigan","city":"Ann Arbor","state":"MI","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"npi":"1164872537","orcid":"0000-0001-9887-3464","openalex":"A5006304513"},"summary":"Marcus Geer is a Hematology physician affiliated with University of Michigan. OpenAlex indexes 44 publications with 268 citations (h-index 8).","overview":null,"focus":{"indications":[],"research_topics":["Hematology"]},"scholarship":{"works_count":44,"cited_by_count":268,"h_index":8,"latest_activity_year":2026,"emerging":true,"source":"works"},"prescribing":{"data_year":2023,"areas_total":1,"areas_shown":1,"areas":[{"area":"Dermatology","share_pct":100,"classes_total":1,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":100,"drugs":[{"name":"Acyclovir","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2023,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":44,"shown":5,"withheld":39,"matched_by":"OpenAlex author record","recent":[{"title":"Enhancing the Safety of Ciltacabtagene Autoleucel in Relapsed Multiple Myeloma (MM):Identification of Potentially Modifiable Risk-Factors Associated with Delayed Neurotoxicity and Non-Relapse Mortality","year":2026,"journal":"Transplantation and Cellular Therapy","source_url":"https://doi.org/10.1016/j.jtct.2025.12.026","status":"verified"},{"title":"Expert Panel Review and Practical Guidance on Biomarker Testing with Engineered Immune Effector Cells","year":2026,"journal":"Transplantation and Cellular Therapy","source_url":"https://doi.org/10.1016/j.jtct.2026.05.005","status":"verified"},{"title":"Impact of Non-Compliance with NIH Consensus Guidelines for PFT Performance in Allogeneic Hematopoietic Cell Transplant Recipients.","year":2026,"journal":"Transplantation and Cellular Therapy","source_url":"https://doi.org/10.1016/j.jtct.2025.12.666","status":"verified"},{"title":"Vorinostat for graft-versus-host disease prevention in pediatric and young adult patients with hematologic malignancies","year":2026,"journal":"JCI Insight","source_url":"https://doi.org/10.1172/jci.insight.210272","status":"verified"},{"title":"Mixed Chimerism Predicts Early Time to Relapse in Myeloablative Conditioning in Allogeneic Hematopoietic Stem Cell Transplant Patients","year":2026,"journal":"Transplantation and Cellular Therapy","source_url":"https://doi.org/10.1016/j.jtct.2025.12.170","status":"verified"}],"source":"works"},"similar":[{"name":"Max Wicha","slug":"max-wicha","institution":"University of Michigan","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/max-wicha","json_url":"https://www.findmykol.com/kol/max-wicha/profile.json"},{"name":"Eva Feldman","slug":"eva-feldman","institution":"University of Michigan","specialty":"Neurology","url":"https://www.findmykol.com/kol/eva-feldman","json_url":"https://www.findmykol.com/kol/eva-feldman/profile.json"},{"name":"Dinesh Khanna","slug":"dinesh-khanna","institution":"University of Michigan","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/dinesh-khanna","json_url":"https://www.findmykol.com/kol/dinesh-khanna/profile.json"},{"name":"Joshua Ehrlich","slug":"joshua-ehrlich","institution":"University of Michigan","specialty":"Ophthalmology","url":"https://www.findmykol.com/kol/joshua-ehrlich","json_url":"https://www.findmykol.com/kol/joshua-ehrlich/profile.json"},{"name":"Joseph Antin","slug":"joseph-antin","institution":"Harvard University","specialty":"Hematology","url":"https://www.findmykol.com/kol/joseph-antin","json_url":"https://www.findmykol.com/kol/joseph-antin/profile.json"},{"name":"Scott Kaufmann","slug":"scott-kaufmann","institution":"Mayo Clinic College of Medicine","specialty":"Hematology","url":"https://www.findmykol.com/kol/scott-kaufmann","json_url":"https://www.findmykol.com/kol/scott-kaufmann/profile.json"},{"name":"Ruben Mesa","slug":"ruben-mesa","institution":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center","specialty":"Hematology","url":"https://www.findmykol.com/kol/ruben-mesa","json_url":"https://www.findmykol.com/kol/ruben-mesa/profile.json"},{"name":"Jaroslaw Maciejewski","slug":"jaroslaw-maciejewski","institution":"Cleveland Clinic","specialty":"Hematology","url":"https://www.findmykol.com/kol/jaroslaw-maciejewski","json_url":"https://www.findmykol.com/kol/jaroslaw-maciejewski/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":39}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}